Neurophth found
in Wuhan, China
THE WORLD'S LEADING OPHTHALMIC GENE THERAPY TECHNOLOGY
Prof. Bin Li (the founder of Neurophth) initiated gene therapy studies for Leber’s hereditary optic neuropathy (LHON) in 2008
IIT clinical data with the longest follow-up time and the largest sample size for LHON gene therapy has been accumulated since 2011
BUILDING A BRIGHTER FUTURE FOR PATIENTS
Becoming a World Leading Company in Ocular Gene Therapy
-
2016
-
10+Ophthalmic gene therapy
drug candidates -
186
Subjects treated in
IIT studies initiated
by Prof. Bin Li
-
4CentresChina
(Wuhan,Suzhou,Shanghai)
+ U.S.
News Center
上一页
下一页
-
2023-09-18Special interview with Chinese and international top neuro-ophthalmologists on LHON Awareness Day
-
2023-09-05Neurophth Secures Australian Approval for Ophthalmic Gene Therapy
-
2023-08-17Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
-
2023-06-08Special interview with Dr. Marcela Ciccioli
-
2023-04-15Neurophth Announces IND Approval by the NMPA for Second Gene Therapy NFS-02 (rAAV2-ND1)
-
2023-04-06Neurophth's Gene Therapy NR082 Completes Initiation of Multiple Clinical Research Centers in U.S.
